As COVID-19 continues to evolve and impact the lives of people around the world, the need for additional effective treatment options continues to be at the forefront of global efforts to combat the disease. Emory University announced today it has entered into an agreement with Pfizer Inc. to advance research that may serve to help address this need and potentially save patients’ lives.
Under the terms of the research collaboration, option and license agreement, Emory University’s Schinazi Laboratory, led by distinguished researcher Raymond Schinazi, and Pfizer will work together to identify and evaluate potential antiviral compounds for the treatment of COVID-19. As part of the collaboration, Pfizer will provide funding to the Schinazi group and collaborate on research to advance the preclinical development of these compounds. If successful, Pfizer will have the option to exercise exclusive rights to the leading clinical candidates and be solely responsible for further development activities.